Chronic Cocaine Use and Parkinson’s Disease: An Interpretative Model
Abstract
:1. Introduction
1.1. Dopaminergic System
1.2. Cocaine Mechanism of Action
1.3. Cocaine Use Disorder (CUD)
1.4. Parkinson’s Disease (PD)
2. An Interpretative Model of the Relationship between CUD and PD
2.1. Dopaminergic Neurotransmission Alterations
2.2. Mitochondrial Dysfunction and Neurotoxicity
2.3. Morphological Plasticity Alterations and Dysregulation of Neurogenesis
3. Discussion
4. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- United Nations Office on Drugs and Crime. World Drug Report 2023; United Nations Publication: New York, NY, USA, 2023. [Google Scholar]
- Hummel, M.; Unterwald, E.M. D1 dopamine receptor: A putative neurochemical and behavioral link to cocaine action. J. Cell. Physiol. 2002, 191, 17–27. [Google Scholar] [CrossRef]
- Blum, K.; Braverman, E.R.; Holder, J.M.; Lubar, J.F.; Monastra, V.J.; Miller, D.; Lubar, J.O.; Chen, T.J.; Comings, D.E. Reward deficiency syndrome: A biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors. J. Psychoact. Drugs 2000, 32 (Suppl. 1), 1–112. [Google Scholar] [CrossRef]
- Blum, K.; Kozlowski, G.P. Ethanol and Neuromodulator Interactions: A Cascade Model of Reward. In Alcohol and Behavior; Ollat, H., Parvez, S., Parvez, H., Eds.; VSP Press: Utrecht, The Netherlands, 1990; pp. 131–149. [Google Scholar]
- Blum, K.; Baron, D.; Lott, L.; Ponce, J.V.; Siwicki, D.; Boyett, B.; Steinberg, B.; Modestino, E.J.; Fried, L.; Hauser, M.; et al. In Search of Reward Deficiency Syndrome (RDS)-free Controls: The “Holy Grail” in Genetic Addiction Risk Testing. Curr. Psychopharmacol. 2020, 9, 7–21. [Google Scholar] [PubMed]
- Michely, J.; Viswanathan, S.; Hauser, T.U.; Delker, L.; Dolan, R.J.; Grefkes, C. The role of dopamine in dynamic effort-reward integration. Neuropsychopharmacology 2020, 45, 1448–1453. [Google Scholar] [CrossRef]
- Guerri, L.; Dobbs, L.K.; da Silva e Silva, D.A.; Meyers, A.; Ge, A.; Lecaj, L.; Djakuduel, C.; Islek, D.; Hipolito, D.; Martinez, A.B.; et al. Low Dopamine D2 Receptor Expression Drives Gene Networks Related to GABA, cAMP, Growth and Neuroinflammation in Striatal Indirect Pathway Neurons. Biol. Psychiatry Glob. Open Sci. 2023, 3, 1104–1115. [Google Scholar] [CrossRef]
- Klein, M.O.; Battagello, D.S.; Cardoso, A.R.; Hauser, D.N.; Bittencourt, J.C.; Correa, R.G. Dopamine: Functions, Signaling, and Association with Neurological Diseases. Cell. Mol. Neurobiol. 2019, 39, 31–59. [Google Scholar] [CrossRef] [PubMed]
- Baik, J.H. Stress and the dopaminergic reward system. Exp. Mol. Med. 2020, 52, 1879–1890. [Google Scholar] [CrossRef] [PubMed]
- Baik, J.-H. Dopamine signaling in reward-related behaviors. Front. Neural Circuits 2013, 7, 152. [Google Scholar] [CrossRef]
- Serafini, R.A.; Pryce, K.D.; Zachariou, V. The Mesolimbic Dopamine System in Chronic Pain and Associated Affective Comorbidities. Biol. Psychiatry 2020, 87, 64–73. [Google Scholar] [CrossRef]
- Le Moal, M.; Simon, H. Mesocorticolimbic dopaminergic network: Functional and regulatory roles. Physiol. Rev. 1991, 71, 155–234. [Google Scholar] [CrossRef]
- Kenny, P.J. Common cellular and molecular mechanisms in obesity and drug addiction. Nat. Rev. Neurosci. 2011, 12, 638–651. [Google Scholar] [CrossRef] [PubMed]
- Pessiglione, M.; Seymour, B.; Flandin, G.; Dolan, R.J.; Frith, C.D. Dopamine-dependent prediction errors underpin reward-seeking behaviour in humans. Nature 2006, 442, 1042–1045. [Google Scholar] [CrossRef] [PubMed]
- Pessiglione, M.; Schmidt, L.; Draganski, B.; Kalisch, R.; Lau, H.; Dolan, R.J.; Frith, C.D. How the Brain Translates Money into Force: A Neuroimaging Study of Subliminal Motivation. Science 2007, 316, 904–906. [Google Scholar] [CrossRef] [PubMed]
- Berridge, K.C.; Kringelbach, M.L. Pleasure Systems in the Brain. Neuron 2015, 86, 646–664. [Google Scholar] [CrossRef] [PubMed]
- Schultz, W. Neuronal Reward and Decision Signals: From Theories to Data. Physiol. Rev. 2015, 95, 853–951. [Google Scholar] [CrossRef] [PubMed]
- Bidwell, L.C.; McClernon, F.J.; Kollins, S.H. Cognitive enhancers for the treatment of ADHD. Pharmacol. Biochem. Behav. 2011, 99, 262–274. [Google Scholar] [CrossRef] [PubMed]
- Brimblecombe, K.R.; Cragg, S.J. The Striosome and Matrix Compartments of the Striatum: A Path through the Labyrinth from Neurochemistry toward Function. ACS Chem. Neurosci. 2017, 8, 235–242. [Google Scholar] [CrossRef] [PubMed]
- Sonne, J.; Reddy, V.; Beato, M.R. Neuroanatomy, Substantia Nigra. Available online: https://www.ncbi.nlm.nih.gov/books/NBK536995/ (accessed on 3 May 2024).
- Roeper, J. Dissecting the diversity of midbrain dopamine neurons. Trends Neurosci. 2013, 36, 336–342. [Google Scholar] [CrossRef] [PubMed]
- Calabresi, P.; Picconi, B.; Tozzi, A.; Ghiglieri, V.; Di Filippo, M. Direct and indirect pathways of basal ganglia: A critical reappraisal. Nat. Neurosci. 2014, 17, 1022–1030. [Google Scholar] [CrossRef] [PubMed]
- Alcaro, A.; Huber, R.; Panksepp, J. Behavioral functions of the mesolimbic dopaminergic system: An affective neuroethological perspective. Brain Res. Rev. 2007, 56, 283–321. [Google Scholar] [CrossRef] [PubMed]
- Nestler, E.J.; Kenny, P.J.; Russo, S.J.; Schaefer, A. Neural and Neuroendocrine Control of the Internal Milieu. In Malenka’s Molecular Neuropharmacology: A Foundation for Clinical Neuroscience, 4e; Nestler, H., Ed.; McGraw-Hill: New York, NY, USA, 2020. [Google Scholar]
- Puopolo, M. The hypothalamic-spinal dopaminergic system: A target for pain modulation. Neural Regen. Res. 2019, 14, 925–930. [Google Scholar] [CrossRef]
- Giuliano, F.; Allard, J. Dopamine and sexual function. Int. J. Impot. Res. 2001, 13, S18–S28. [Google Scholar] [CrossRef]
- Brandão, M.L.; Coimbra, N.C. Understanding the role of dopamine in conditioned and unconditioned fear. Rev. Neurosci. 2019, 30, 325–337. [Google Scholar] [CrossRef]
- Hosenbocus, S.; Chahal, R. A review of executive function deficits and pharmacological management in children and adolescents. J. Can. Acad. Child Adolesc. Psychiatry 2012, 21, 223–229. [Google Scholar] [PubMed]
- Diamond, A. Executive functions. Annu. Rev. Psychol. 2013, 64, 135–168. [Google Scholar] [CrossRef]
- Robinson, S.; Goddard, L.; Dritschel, B.; Wisley, M.; Howlin, P. Executive functions in children with autism spectrum disorders. Brain Cogn. 2009, 71, 362–368. [Google Scholar] [CrossRef] [PubMed]
- Ozonoff, S.; Cook, I.; Coon, H.; Dawson, G.; Joseph, R.M.; Klin, A.; McMahon, W.M.; Minshew, N.; Munson, J.A.; Pennington, B.F.; et al. Performance on Cambridge Neuropsychological Test Automated Battery subtests sensitive to frontal lobe function in people with autistic disorder: Evidence from the Collaborative Programs of Excellence in Autism network. J. Autism Dev. Disord. 2004, 34, 139–150. [Google Scholar] [CrossRef]
- Friedman, N.P.; Robbins, T.W. The role of prefrontal cortex in cognitive control and executive function. Neuropsychopharmacology 2022, 47, 72–89. [Google Scholar] [CrossRef]
- Phillips, K.; Luk, A.; Soor, G.S.; Abraham, J.R.; Leong, S.; Butany, J. Cocaine cardiotoxicity: A review of the pathophysiology, pathology, and treatment options. Am. J. Cardiovasc. Drugs 2009, 9, 177–196. [Google Scholar] [CrossRef]
- Drake, L.R.; Scott, P.J.H. DARK Classics in Chemical Neuroscience: Cocaine. ACS Chem. Neurosci. 2018, 9, 2358–2372. [Google Scholar] [CrossRef] [PubMed]
- Dinis-Oliveira, R.J.; Carvalho, F.; Duarte, J.A.; Proença, J.B.; Santos, A.; Magalhães, T. Clinical and forensic signs related to cocaine abuse. Curr. Drug Abus. Rev. 2012, 5, 64–83. [Google Scholar] [CrossRef]
- Kuhar, M.J.; Ritz, M.C.; Boja, J.W. The dopamine hypothesis of the reinforcing properties of cocaine. Trends Neurosci. 1991, 14, 299–302. [Google Scholar] [CrossRef] [PubMed]
- Lluch, J.; Rodríguez-Arias, M.; Aguilar, M.A.; Miñarro, J. Role of dopamine and glutamate receptors in cocaine-induced social effects in isolated and grouped male OF1 mice. Pharmacol. Biochem. Behav. 2005, 82, 478–487. [Google Scholar] [CrossRef] [PubMed]
- Anastasio, N.C.; Sholler, D.J.; Fox, R.G.; Stutz, S.J.; Merritt, C.R.; Bjork, J.M.; Moeller, F.G.; Cunningham, K.A. Suppression of cocaine relapse-like behaviors upon pimavanserin and lorcaserin co-administration. Neuropharmacology 2020, 168, 108009. [Google Scholar] [CrossRef] [PubMed]
- Gannon, B.M.; Sulima, A.; Rice, K.C.; Collins, G.T. Inhibition of Cocaine and 3,4-Methylenedioxypyrovalerone (MDPV) Self-Administration by Lorcaserin Is Mediated by 5-HT2C Receptors in Rats. J. Pharmacol. Exp. Ther. 2018, 364, 359–366. [Google Scholar] [CrossRef] [PubMed]
- Filip, M.; Bubar, M.J.; Cunningham, K.A. Contribution of serotonin (5-hydroxytryptamine; 5-HT) 5-HT2 receptor subtypes to the hyperlocomotor effects of cocaine: Acute and chronic pharmacological analyses. J. Pharmacol. Exp. Ther. 2004, 310, 1246–1254. [Google Scholar] [CrossRef] [PubMed]
- Okada, T.; Shioda, K.; Makiguchi, A.; Suda, S. Risperidone and 5-HT2A Receptor Antagonists Attenuate and Reverse Cocaine-Induced Hyperthermia in Rats. Int. J. Neuropsychopharmacol. 2020, 23, 811–820. [Google Scholar] [CrossRef] [PubMed]
- Yang, J.; Li, M.D. Association and interaction analyses of 5-HT3 receptor and serotonin transporter genes with alcohol, cocaine, and nicotine dependence using the SAGE data. Hum. Genet. 2014, 133, 905–918. [Google Scholar] [CrossRef]
- Ait-Daoud, N.; Johnson, B.A.; Prihoda, T.J.; Hargita, I.D. Combining ondansetron and naltrexone reduces craving among biologically predisposed alcoholics: Preliminary clinical evidence. Psychopharmacology 2001, 154, 23–27. [Google Scholar] [CrossRef]
- Liang, D.Y.; Li, X.; Clark, J.D. 5-hydroxytryptamine type 3 receptor modulates opioid-induced hyperalgesia and tolerance in mice. Anesthesiology 2011, 114, 1180–1189. [Google Scholar] [CrossRef] [PubMed]
- Laurini, E.; Marson, D.; Dal Col, V.; Fermeglia, M.; Mamolo, M.G.; Zampieri, D.; Vio, L.; Pricl, S. Another brick in the wall. Validation of the σ1 receptor 3D model by computer-assisted design, synthesis, and activity of new σ1 ligands. Mol. Pharm. 2012, 9, 3107–3126. [Google Scholar] [CrossRef]
- Nguyen, L.; Lucke-Wold, B.P.; Mookerjee, S.A.; Cavendish, J.Z.; Robson, M.J.; Scandinaro, A.L.; Matsumoto, R.R. Role of sigma-1 receptors in neurodegenerative diseases. J. Pharmacol. Sci. 2015, 127, 17–29. [Google Scholar] [CrossRef] [PubMed]
- Mori, T.; Hayashi, T.; Hayashi, E.; Su, T.P. Sigma-1 receptor chaperone at the ER-mitochondrion interface mediates the mitochondrion-ER-nucleus signaling for cellular survival. PLoS ONE 2013, 8, e76941. [Google Scholar] [CrossRef]
- Tsai, S.-Y.A.; Pokrass, M.J.; Klauer, N.R.; De Credico, N.E.; Su, T.-P. Sigma-1 receptor chaperones in neurodegenerative and psychiatric disorders. Expert Opin. Ther. Targets 2014, 18, 1461–1476. [Google Scholar] [CrossRef]
- Kourrich, S.; Su, T.P.; Fujimoto, M.; Bonci, A. The sigma-1 receptor: Roles in neuronal plasticity and disease. Trends Neurosci. 2012, 35, 762–771. [Google Scholar] [CrossRef]
- Guo, L.; Zhen, X. Sigma-2 receptor ligands: Neurobiological effects. Curr. Med. Chem. 2015, 22, 989–1003. [Google Scholar] [CrossRef]
- Ortinski, P.I. Cocaine-induced changes in NMDA receptor signaling. Mol. Neurobiol. 2014, 50, 494–506. [Google Scholar] [CrossRef]
- Crits-Christoph, P.; Newberg, A.; Wintering, N.; Ploessl, K.; Gibbons, M.B.; Ring-Kurtz, S.; Gallop, R.; Present, J. Dopamine transporter levels in cocaine dependent subjects. Drug Alcohol. Depend. 2008, 98, 70–76. [Google Scholar] [CrossRef] [PubMed]
- Yoo, J.H.; Kitchen, I.; Bailey, A. The endogenous opioid system in cocaine addiction: What lessons have opioid peptide and receptor knockout mice taught us? Br. J. Pharmacol. 2012, 166, 1993–2014. [Google Scholar] [CrossRef] [PubMed]
- Knuepfer, M.M. Cardiovascular disorders associated with cocaine use: Myths and truths. Pharmacol. Ther. 2003, 97, 181–222. [Google Scholar] [CrossRef]
- Kim, S.T.; Park, T. Acute and Chronic Effects of Cocaine on Cardiovascular Health. Int. J. Mol. Sci. 2019, 20, 584. [Google Scholar] [CrossRef] [PubMed]
- Wang, J.; Deng, X.; Wu, Y.; Huang, Y.; Hou, S.; Zhang, Y.; Qiu, T.; Tong, J.; Chen, X. Sub-lethal toxicity and elimination of the cocaine metabolite, benzoylecgonine: A narrative review. Ann. Palliat. Med. 2021, 10, 6936–6947. [Google Scholar] [CrossRef] [PubMed]
- Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States: Results from the 2016 National Survey on Drug Use and Health (HHS Publication No. SMA 17-5044, NSDUH Series H-52); Center for Behavioral Health Statistics and Quality: Rockville, MD, USA, 2018.
- Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States: Results from the 2019 National Survey on Drug Use and Health; SAMHSA: Rockville, ML, USA, 2020.
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5; American Psychiatric Association: Arlington, VA, USA, 2013. [Google Scholar]
- Ross, S.; Peselow, E. Co-occurring psychotic and addictive disorders: Neurobiology and diagnosis. Clin. Neuropharmacol. 2012, 35, 235–243. [Google Scholar] [CrossRef] [PubMed]
- Kelly, T.M.; Daley, D.C. Integrated treatment of substance use and psychiatric disorders. Soc. Work Public Health 2013, 28, 388–406. [Google Scholar] [CrossRef] [PubMed]
- Arias, F.; Szerman, N.; Vega, P.; Mesias, B.; Basurte, I.; Morant, C.; Ochoa, E.; Poyo, F.; Babin, F. Cocaine abuse or dependency and other psychiatric disorders. Madrid study on dual pathology. Rev. Psiquiatr. Salud Ment. 2013, 6, 121–128. [Google Scholar] [CrossRef] [PubMed]
- Torrens, M.; Gilchrist, G.; Domingo-Salvany, A. Psychiatric comorbidity in illicit drug users: Substance-induced versus independent disorders. Drug Alcohol Depend. 2011, 113, 147–156. [Google Scholar] [CrossRef] [PubMed]
- Pettinati, H.M.; O’Brien, C.P.; Dundon, W.D. Current status of co-occurring mood and substance use disorders: A new therapeutic target. Am. J. Psychiatry 2013, 170, 23–30. [Google Scholar] [CrossRef] [PubMed]
- De Alwis, D.; Lynskey, M.T.; Reiersen, A.M.; Agrawal, A. Attention-deficit/hyperactivity disorder subtypes and substance use and use disorders in NESARC. Addict. Behav. 2014, 39, 1278–1285. [Google Scholar] [CrossRef] [PubMed]
- Hartz, S.M.; Pato, C.N.; Medeiros, H.; Cavazos-Rehg, P.; Sobell, J.L.; Knowles, J.A.; Bierut, L.J.; Pato, M.T. Comorbidity of severe psychotic disorders with measures of substance use. JAMA Psychiatry 2014, 71, 248–254. [Google Scholar] [CrossRef] [PubMed]
- Pennay, A.; Cameron, J.; Reichert, T.; Strickland, H.; Lee, N.K.; Hall, K.; Lubman, D.I. A systematic review of interventions for co-occurring substance use disorder and borderline personality disorder. J. Subst. Abus. Treat. 2011, 41, 363–373. [Google Scholar] [CrossRef]
- Pereira, R.B.; Andrade, P.B.; Valentão, P. A Comprehensive View of the Neurotoxicity Mechanisms of Cocaine and Ethanol. Neurotox. Res. 2015, 28, 253–267. [Google Scholar] [CrossRef] [PubMed]
- Clark, K.H.; Wiley, C.A.; Bradberry, C.W. Psychostimulant abuse and neuroinflammation: Emerging evidence of their interconnection. Neurotox. Res. 2013, 23, 174–188. [Google Scholar] [CrossRef] [PubMed]
- Cenci, D.; Carbone, M.G.; Callegari, C.; Maremmani, I. Psychomotor Symptoms in Chronic Cocaine Users: An Interpretative Model. Int. J. Environ. Res. Public Health 2022, 19, 1897. [Google Scholar] [CrossRef] [PubMed]
- Beitz, J.M. Parkinson’s disease: A review. Front. Biosci. 2014, 6, 65–74. [Google Scholar] [CrossRef]
- Pagano, G.; Ferrara, N.; Brooks, D.J.; Pavese, N. Age at onset and Parkinson disease phenotype. Neurology 2016, 86, 1400–1407. [Google Scholar] [CrossRef] [PubMed]
- Sung, V.W.; Nicholas, A.P. Nonmotor symptoms in Parkinson’s disease: Expanding the view of Parkinson’s disease beyond a pure motor, pure dopaminergic problem. Neurol. Clin. 2013, 31, S1–S16. [Google Scholar] [CrossRef] [PubMed]
- DeMaagd, G.; Philip, A. Parkinson’s Disease and Its Management: Part 1: Disease Entity, Risk Factors, Pathophysiology, Clinical Presentation, and Diagnosis. Pharm. Ther. 2015, 40, 504–532. [Google Scholar]
- Samii, A.; Nutt, J.G.; Ransom, B.R. Parkinson’s disease. Lancet 2004, 363, 1783–1793. [Google Scholar] [CrossRef]
- Lynch-Day, M.A.; Mao, K.; Wang, K.; Zhao, M.; Klionsky, D.J. The role of autophagy in Parkinson’s disease. Cold Spring Harb. Perspect. Med. 2012, 2, a009357. [Google Scholar] [CrossRef] [PubMed]
- Doblado, L.; Lueck, C.; Rey, C.; Samhan-Arias, A.K.; Prieto, I.; Stacchiotti, A.; Monsalve, M. Mitophagy in Human Diseases. Int. J. Mol. Sci. 2021, 22, 3903. [Google Scholar] [CrossRef] [PubMed]
- Lampinen, R.; Belaya, I.; Saveleva, L.; Liddell, J.R.; Rait, D.; Huuskonen, M.T.; Giniatullina, R.; Sorvari, A.; Soppela, L.; Mikhailov, N.; et al. Neuron-astrocyte transmitophagy is altered in Alzheimer’s disease. Neurobiol. Dis. 2022, 170, 105753. [Google Scholar] [CrossRef]
- Morales, I.; Sanchez, A.; Puertas-Avendaño, R.; Rodriguez-Sabate, C.; Perez-Barreto, A.; Rodriguez, M. Neuroglial transmitophagy and Parkinson’s disease. Glia 2020, 68, 2277–2299. [Google Scholar] [CrossRef]
- Henrich, M.T.; Oertel, W.H.; Surmeier, D.J.; Geibl, F.F. Mitochondrial dysfunction in Parkinson’s disease—A key disease hallmark with therapeutic potential. Mol. Neurodegener. 2023, 18, 83. [Google Scholar] [CrossRef] [PubMed]
- Bayer, T.A. Proteinopathies, a core concept for understanding and ultimately treating degenerative disorders? Eur. Neuropsychopharmacol. 2015, 25, 713–724. [Google Scholar] [CrossRef]
- Lim, K.-L.; Tan, J.M.M. Role of the ubiquitin proteasome system in Parkinson’s disease. BMC Biochem. 2007, 8, S13. [Google Scholar] [CrossRef]
- Fritsch, T.; Smyth, K.A.; Wallendal, M.S.; Hyde, T.; Leo, G.; Geldmacher, D.S. Parkinson disease: Research update and clinical management. South. Med. J. 2012, 105, 650–656. [Google Scholar] [CrossRef]
- Simon, D.K.; Tanner, C.M.; Brundin, P. Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology. Clin. Geriatr. Med. 2020, 36, 1–12. [Google Scholar] [CrossRef]
- Hawkes, C.H.; Del Tredici, K.; Braak, H. Parkinson’s disease: A dual-hit hypothesis. Neuropathol. Appl. Neurobiol. 2007, 33, 599–614. [Google Scholar] [CrossRef] [PubMed]
- United Nations Office on Drugs and Crime. World Drug Report 2021; UNODC: Vienna, Austria, 2021. [Google Scholar]
- United Nations International Drug Control Programme. World Drug Report; Boom Koninklijke Uitgevers: Stationsweg, The Netherlands, 2006; Volume 1. [Google Scholar]
- Verma, V. Classic Studies on the Interaction of Cocaine and the Dopamine Transporter. Clin. Psychopharmacol. Neurosci. 2015, 13, 227–238. [Google Scholar] [CrossRef] [PubMed]
- Bu, M.; Farrer, M.J.; Khoshbouei, H. Dynamic control of the dopamine transporter in neurotransmission and homeostasis. NPJ Park. Dis. 2021, 7, 22. [Google Scholar] [CrossRef]
- Luo, Z.; Volkow, N.D.; Heintz, N.; Pan, Y.; Du, C. Acute cocaine induces fast activation of D1 receptor and progressive deactivation of D2 receptor striatal neurons: In vivo optical microprobe [Ca2+]i imaging. J. Neurosci. 2011, 31, 13180–13190. [Google Scholar] [CrossRef] [PubMed]
- Little, K.Y.; McLaughlin, D.P.; Zhang, L.; McFinton, P.R.; Dalack, G.W.; Cook, E.H., Jr.; Cassin, B.J.; Watson, S.J. Brain dopamine transporter messenger RNA and binding sites in cocaine users: A postmortem study. Arch. Gen. Psychiatry 1998, 55, 793–799. [Google Scholar] [CrossRef]
- Mash, D.C.; Pablo, J.; Ouyang, Q.; Hearn, W.L.; Izenwasser, S. Dopamine transport function is elevated in cocaine users. J. Neurochem. 2002, 81, 292–300. [Google Scholar] [CrossRef]
- Staley, J.K.; Hearn, W.L.; Ruttenber, A.J.; Wetli, C.V.; Mash, D.C. High affinity cocaine recognition sites on the dopamine transporter are elevated in fatal cocaine overdose victims. J. Pharmacol. Exp. Ther. 1994, 271, 1678–1685. [Google Scholar]
- Malison, R.T.; Best, S.E.; van Dyck, C.H.; McCance, E.F.; Wallace, E.A.; Laruelle, M.; Baldwin, R.M.; Seibyl, J.P.; Price, L.H.; Kosten, T.R.; et al. Elevated striatal dopamine transporters during acute cocaine abstinence as measured by [123I] beta-CIT SPECT. Am. J. Psychiatry 1998, 155, 832–834. [Google Scholar] [CrossRef] [PubMed]
- Maroteaux, L.; Scheller, R.H. The rat brain synucleins; family of proteins transiently associated with neuronal membrane. Mol. Brain Res. 1991, 11, 335–343. [Google Scholar] [CrossRef]
- Lavedan, C. The synuclein family. Genome Res. 1998, 8, 871–880. [Google Scholar] [CrossRef]
- Clayton, D.F.; George, J.M. Synucleins in synaptic plasticity and neurodegenerative disorders. J. Neurosci. Res. 1999, 58, 120–129. [Google Scholar]
- Jenco, J.M.; Rawlingson, A.; Daniels, B.; Morris, A.J. Regulation of phospholipase D2: Selective inhibition of mammalian phospholipase D isoenzymes by alpha- and beta-synucleins. Biochemistry 1998, 37, 4901–4909. [Google Scholar] [CrossRef] [PubMed]
- Lee, F.J.; Liu, F.; Pristupa, Z.B.; Niznik, H.B. Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB J. 2001, 15, 916–926. [Google Scholar] [CrossRef]
- Mash, D.C.; Ouyang, Q.; Pablo, J.; Basile, M.; Izenwasser, S.; Lieberman, A.; Perrin, R.J. Cocaine abusers have an overexpression of alpha-synuclein in dopamine neurons. J. Neurosci. 2003, 23, 2564–2571. [Google Scholar] [CrossRef] [PubMed]
- Sanchez-Guajardo, V.; Barnum, C.J.; Tansey, M.G.; Romero-Ramos, M. Neuroimmunological processes in Parkinson’s disease and their relation to alpha-synuclein: Microglia as the referee between neuronal processes and peripheral immunity. ASN Neuro 2013, 5, 113–139. [Google Scholar] [CrossRef]
- Volkow, N.D.; Fowler, J.S.; Wolf, A.P.; Schlyer, D.; Shiue, C.Y.; Alpert, R.; Dewey, S.L.; Logan, J.; Bendriem, B.; Christman, D.; et al. Effects of chronic cocaine abuse on postsynaptic dopamine receptors. Am. J. Psychiatry 1990, 147, 719–724. [Google Scholar] [CrossRef]
- Volkow, N.D.; Tomasi, D.; Wang, G.J.; Logan, J.; Alexoff, D.L.; Jayne, M.; Fowler, J.S.; Wong, C.; Yin, P.; Du, C. Stimulant-induced dopamine increases are markedly blunted in active cocaine abusers. Mol. Psychiatry 2014, 19, 1037–1043. [Google Scholar] [CrossRef]
- Vaillancourt, D.E.; Schonfeld, D.; Kwak, Y.; Bohnen, N.I.; Seidler, R. Dopamine overdose hypothesis: Evidence and clinical implications. Mov. Disord. 2013, 28, 1920–1929. [Google Scholar] [CrossRef]
- Juárez Olguín, H.; Calderón Guzmán, D.; Hernández García, E.; Barragán Mejía, G. The Role of Dopamine and Its Dysfunction as a Consequence of Oxidative Stress. Oxidative Med. Cell. Longev. 2016, 2016, 9730467. [Google Scholar] [CrossRef]
- Little, K.Y.; Ramssen, E.; Welchko, R.; Volberg, V.; Roland, C.J.; Cassin, B. Decreased brain dopamine cell numbers in human cocaine users. Psychiatry Res. 2009, 168, 173–180. [Google Scholar] [CrossRef] [PubMed]
- Bauer, L.O. Psychomotor and electroencephalographic sequelae of cocaine dependence. NIDA Res. Monogr. 1996, 163, 66–93. [Google Scholar] [PubMed]
- Bartzokis, G.; Beckson, M.; Ling, W. Clinical and MRI evaluation of psychostimulant neurotoxicity. NIDA Res. Monogr. 1996, 163, 300–317. [Google Scholar] [PubMed]
- Pascual-Leone, A.; Dhuna, A.; Anderson, D.C. Cerebral atrophy in habitual cocaine abusers: A planimetric CT study. Neurology 1991, 41, 34–38. [Google Scholar] [CrossRef]
- Volkow, N.D.; Hitzemann, R.; Wang, G.J.; Fowler, J.S.; Wolf, A.P.; Dewey, S.L.; Handlesman, L. Long-term frontal brain metabolic changes in cocaine abusers. Synapse 1992, 11, 184–190. [Google Scholar] [CrossRef] [PubMed]
- Granado, N.; Ares-Santos, S.; O’Shea, E.; Vicario-Abejón, C.; Colado, M.I.; Moratalla, R. Selective Vulnerability in Striosomes and in the Nigrostriatal Dopaminergic Pathway After Methamphetamine Administration. Neurotox. Res. 2010, 18, 48–58. [Google Scholar] [CrossRef] [PubMed]
- Vos, M. Mitochondrial Complex I deficiency: Guilty in Parkinson’s disease. Signal Transduct. Target. Ther. 2022, 7, 136. [Google Scholar] [CrossRef] [PubMed]
- Cadet, J.L.; Brannock, C. Invited Review Free radicals and the pathobiology of brain dopamine systems. Neurochem. Int. 1998, 32, 117–131. [Google Scholar] [CrossRef] [PubMed]
- Simola, N.; Morelli, M.; Carta, A.R. The 6-Hydroxydopamine model of parkinson’s disease. Neurotox. Res. 2007, 11, 151–167. [Google Scholar] [CrossRef] [PubMed]
- Bernstein, A.I.; Stout, K.A.; Miller, G.W. The vesicular monoamine transporter 2: An underexplored pharmacological target. Neurochem. Int. 2014, 73, 89–97. [Google Scholar] [CrossRef] [PubMed]
- Kanner, B.I.; Schuldiner, S. Mechanism of transport and storage of neurotransmitters. CRC Crit. Rev. Biochem. 1987, 22, 1–38. [Google Scholar] [CrossRef] [PubMed]
- Miller, G.W.; Gainetdinov, R.R.; Levey, A.I.; Caron, M.G. Dopamine transporters and neuronal injury. Trends Pharmacol. Sci. 1999, 20, 424–429. [Google Scholar] [CrossRef] [PubMed]
- Fleckenstein, A.E.; Hanson, G.R. Impact of psychostimulants on vesicular monoamine transporter function. Eur. J. Pharmacol. 2003, 479, 283–289. [Google Scholar] [CrossRef] [PubMed]
- Dauer, W.; Przedborski, S. Parkinson’s disease: Mechanisms and models. Neuron 2003, 39, 889–909. [Google Scholar] [CrossRef] [PubMed]
- Chen, M.K.; Kuwabara, H.; Zhou, Y.; Adams, R.J.; Brasic, J.R.; McGlothan, J.L.; Verina, T.; Burton, N.C.; Alexander, M.; Kumar, A.; et al. VMAT2 and dopamine neuron loss in a primate model of Parkinson’s disease. J. Neurochem. 2008, 105, 78–90. [Google Scholar] [CrossRef]
- Ebrahimi-Fakhari, D.; Cantuti-Castelvetri, I.; Fan, Z.; Rockenstein, E.; Masliah, E.; Hyman, B.T.; McLean, P.J.; Unni, V.K. Distinct roles in vivo for the ubiquitin-proteasome system and the autophagy-lysosomal pathway in the degradation of α-synuclein. J. Neurosci. 2011, 31, 14508–14520. [Google Scholar] [CrossRef]
- Dawson, T.M.; Dawson, V.L. The role of parkin in familial and sporadic Parkinson’s disease. Mov. Disord. 2010, 25 (Suppl. 1), S32–S39. [Google Scholar] [CrossRef]
- Ge, P.; Dawson, V.L.; Dawson, T.M. PINK1 and Parkin mitochondrial quality control: A source of regional vulnerability in Parkinson’s disease. Mol. Neurodegener. 2020, 15, 20. [Google Scholar] [CrossRef] [PubMed]
- Deas, E.; Wood, N.W.; Plun-Favreau, H. Mitophagy and Parkinson’s disease: The PINK1-parkin link. Biochim. Biophys. Acta 2011, 1813, 623–633. [Google Scholar] [CrossRef]
- Pickrell, A.M.; Youle, R.J. The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson’s disease. Neuron 2015, 85, 257–273. [Google Scholar] [CrossRef]
- Wang, Q.; Liu, Y.; Zhou, J. Neuroinflammation in Parkinson’s disease and its potential as therapeutic target. Transl. Neurodegener. 2015, 4, 19. [Google Scholar] [CrossRef]
- McGeer, P.L.; Itagaki, S.; Boyes, B.E.; McGeer, E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology 1988, 38, 1285–1291. [Google Scholar] [CrossRef]
- Antonini, A.; Leenders, K.L. Dopamine D2 receptors in normal human brain: Effect of age measured by positron emission tomography (PET) and [11C]-raclopride. Ann. N. Y. Acad. Sci. 1993, 695, 81–85. [Google Scholar] [CrossRef] [PubMed]
- Leal, M.C.; Casabona, J.C.; Puntel, M.; Pitossi, F.J. Interleukin-1β and tumor necrosis factor-α: Reliable targets for protective therapies in Parkinson’s Disease? Front. Cell. Neurosci. 2013, 7, 53. [Google Scholar] [CrossRef]
- Tansey, M.G.; McCoy, M.K.; Frank-Cannon, T.C. Neuroinflammatory mechanisms in Parkinson’s disease: Potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp. Neurol. 2007, 208, 1–25. [Google Scholar] [CrossRef] [PubMed]
- Saijo, K.; Winner, B.; Carson, C.T.; Collier, J.G.; Boyer, L.; Rosenfeld, M.G.; Gage, F.H.; Glass, C.K. A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell 2009, 137, 47–59. [Google Scholar] [CrossRef] [PubMed]
- Vicente-Rodriguez, M.; Herradon, G.; Ferrer-Alcon, M.; Uribarri, M.; Perez-Garcia, C. Chronic Cocaine Use Causes Changes in the Striatal Proteome Depending on the Endogenous Expression of Pleiotrophin. Chem. Res. Toxicol. 2015, 28, 1443–1454. [Google Scholar] [CrossRef] [PubMed]
- Wang, X. Pleiotrophin: Activity and mechanism. Adv. Clin. Chem. 2020, 98, 51–89. [Google Scholar] [CrossRef] [PubMed]
- Cai, Y.; Yang, L.; Niu, F.; Liao, K.; Buch, S. Role of Sigma-1 Receptor in Cocaine Abuse and Neurodegenerative Disease. Adv. Exp. Med. Biol. 2017, 964, 163–175. [Google Scholar] [CrossRef] [PubMed]
- Villalba, R.M.; Smith, Y. Differential striatal spine pathology in Parkinson’s disease and cocaine addiction: A key role of dopamine? Neuroscience 2013, 251, 2–20. [Google Scholar] [CrossRef] [PubMed]
- Dobi, A.; Seabold, G.K.; Christensen, C.H.; Bock, R.; Alvarez, V.A. Cocaine-induced plasticity in the nucleus accumbens is cell specific and develops without prolonged withdrawal. J. Neurosci. 2011, 31, 1895–1904. [Google Scholar] [CrossRef] [PubMed]
- Dumitriu, D.; LaPlant, Q.; Grossman, Y.S.; Dias, C.; Janssen, W.G.; Russo, S.J.; Morrison, J.H.; Nestler, E.J. Subregional, Dendritic Compartment, and Spine Subtype Specificity in Cocaine Regulation of Dendritic Spines in the Nucleus Accumbens. J. Neurosci. 2012, 32, 6957. [Google Scholar] [CrossRef] [PubMed]
- Rial, D.; Morató, X.; Real, J.I.; Gonçalves, F.Q.; Stagljar, I.; Pereira, F.C.; Fernández-Dueñas, V.; Cunha, R.A.; Ciruela, F. Parkinson’s disease-associated GPR37 receptor regulates cocaine-mediated synaptic depression in corticostriatal synapses. Neurosci. Lett. 2017, 638, 162–166. [Google Scholar] [CrossRef] [PubMed]
- Pulipparacharuvil, S.; Renthal, W.; Hale, C.F.; Taniguchi, M.; Xiao, G.; Kumar, A.; Russo, S.J.; Sikder, D.; Dewey, C.M.; Davis, M.M.; et al. Cocaine Regulates MEF2 to Control Synaptic and Behavioral Plasticity. Neuron 2008, 59, 621–633. [Google Scholar] [CrossRef]
- Kolb, B.; Gorny, G.; Li, Y.; Samaha, A.-N.; Robinson, T.E. Amphetamine or cocaine limits the ability of later experience to promote structural plasticity in the neocortex and nucleus accumbens. Proc. Natl. Acad. Sci. USA 2003, 100, 10523–10528. [Google Scholar] [CrossRef] [PubMed]
- Lee, K.W.; Kim, Y.; Kim, A.M.; Helmin, K.; Nairn, A.C.; Greengard, P. Cocaine-induced dendritic spine formation in D1 and D2 dopamine receptor-containing medium spiny neurons in nucleus accumbens. Proc. Natl. Acad. Sci. USA 2006, 103, 3399–3404. [Google Scholar] [CrossRef] [PubMed]
- Li, J.; Liu, N.; Lu, K.; Zhang, L.; Gu, J.; Guo, F.; An, S.; Zhang, L.; Zhang, L. Cocaine-induced dendritic remodeling occurs in both D1 and D2 dopamine receptor-expressing neurons in the nucleus accumbens. Neurosci. Lett. 2012, 517, 118–122. [Google Scholar] [CrossRef] [PubMed]
- Tian, X.; Kai, L.; Hockberger, P.E.; Wokosin, D.L.; Surmeier, D.J. MEF-2 regulates activity-dependent spine loss in striatopallidal medium spiny neurons. Mol. Cell. Neurosci. 2010, 44, 94–108. [Google Scholar] [CrossRef]
- Villalba, R.M.; Smith, Y. Striatal spine plasticity in Parkinson’s disease. Front. Neuroanat. 2010, 4, 133. [Google Scholar] [CrossRef] [PubMed]
- Siniscalchi, A.; Bonci, A.; Mercuri, N.B.; De Siena, A.; De Sarro, G.; Malferrari, G.; Diana, M.; Gallelli, L. Cocaine dependence and stroke: Pathogenesis and management. Curr. Neurovascular Res. 2015, 12, 163–172. [Google Scholar] [CrossRef]
- Su, J.; Li, J.; Li, W.; Altura, B.T.; Altura, B.M. Cocaine induces apoptosis in cerebral vascular muscle cells: Potential roles in strokes and brain damage. Eur. J. Pharmacol. 2003, 482, 61–66. [Google Scholar] [CrossRef] [PubMed]
- Liu, X.; Matochik, J.A.; Cadet, J.L.; London, E.D. Smaller volume of prefrontal lobe in polysubstance abusers: A magnetic resonance imaging study. Neuropsychopharmacology 1998, 18, 243–252. [Google Scholar] [CrossRef] [PubMed]
- Franklin, T.R.; Acton, P.D.; Maldjian, J.A.; Gray, J.D.; Croft, J.R.; Dackis, C.A.; O’Brien, C.P.; Childress, A.R. Decreased gray matter concentration in the insular, orbitofrontal, cingulate, and temporal cortices of cocaine patients. Biol. Psychiatry 2002, 51, 134–142. [Google Scholar] [CrossRef] [PubMed]
- Gottschalk, P.C.; Kosten, T.R. Cerebral perfusion defects in combined cocaine and alcohol dependence. Drug Alcohol Depend. 2002, 68, 95–104. [Google Scholar] [CrossRef] [PubMed]
- Volkow, N.D.; Mullani, N.; Gould, K.L.; Adler, S.; Krajewski, K. Cerebral blood flow in chronic cocaine users: A study with positron emission tomography. Br. J. Psychiatry 1988, 152, 641–648. [Google Scholar] [CrossRef] [PubMed]
- Ernst, T.; Chang, L.; Oropilla, G.; Gustavson, A.; Speck, O. Cerebral perfusion abnormalities in abstinent cocaine abusers: A perfusion MRI and SPECT study. Psychiatry Res. 2000, 99, 63–74. [Google Scholar] [CrossRef] [PubMed]
- Barroso-Moguel, R.; Mendez-Armenta, M.; Villeda-Hernandez, J.; Nava-Ruiz, C.; Santamaria, A. Brain lesions induced by chronic cocaine administration to rats. Prog. Neuropsychopharmacol. Biol. Psychiatry 2002, 26, 59–63. [Google Scholar] [CrossRef] [PubMed]
- Tamrazi, B.; Almast, J. Your brain on drugs: Imaging of drug-related changes in the central nervous system. Radiographics 2012, 32, 701–719. [Google Scholar] [CrossRef] [PubMed]
- Ersche, K.D.; Jones, P.S.; Williams, G.B.; Robbins, T.W.; Bullmore, E.T. Cocaine dependence: A fast-track for brain ageing? Mol. Psychiatry 2013, 18, 134–135. [Google Scholar] [CrossRef] [PubMed]
- Gottwald, B.; Wilde, B.; Mihajlovic, Z.; Mehdorn, H.M. Evidence for distinct cognitive deficits after focal cerebellar lesions. J. Neurol. Neurosurg. Psychiatry 2004, 75, 1524–1531. [Google Scholar] [CrossRef] [PubMed]
- Hester, R.; Garavan, H. Executive dysfunction in cocaine addiction: Evidence for discordant frontal, cingulate, and cerebellar activity. J. Neurosci. 2004, 24, 11017–11022. [Google Scholar] [CrossRef] [PubMed]
- Smelson, D.A.; Roy, A.; Santana, S.; Engelhart, C. Neuropsychological deficits in withdrawn cocaine-dependent males. Am. J. Drug Alcohol Abus 1999, 25, 377–381. [Google Scholar] [CrossRef]
- Beheshti, I. Cocaine Destroys Gray Matter Brain Cells and Accelerates Brain Aging. Biology 2023, 12, 752. [Google Scholar] [CrossRef]
- Wen, S.; Aki, T.; Funakoshi, T.; Unuma, K.; Uemura, K. Role of Mitochondrial Dynamics in Cocaine’s Neurotoxicity. Int. J. Mol. Sci. 2022, 23, 5418. [Google Scholar] [CrossRef] [PubMed]
- Ferreira, C.; Almeida, C.; Tenreiro, S.; Quintas, A. Neuroprotection or Neurotoxicity of Illicit Drugs on Parkinson’s Disease. Life 2020, 10, 86. [Google Scholar] [CrossRef]
- Arendt, R.E.; Minnes, S.; Singer, L.T. Fetal Cocaine Exposure: Neurologic Effects and Sensory-Motor Delays. Child. Prenat. Drug Expo. 1996, 16, 129–144. [Google Scholar] [CrossRef]
- Little, K.Y.; Krolewski, D.M.; Zhang, L.; Cassin, B.J. Loss of striatal vesicular monoamine transporter protein (VMAT2) in human cocaine users. Am. J. Psychiatry 2003, 160, 47–55. [Google Scholar] [CrossRef] [PubMed]
- Connolly, C.G.; Bell, R.P.; Foxe, J.J.; Garavan, H. Dissociated grey matter changes with prolonged addiction and extended abstinence in cocaine users. PLoS ONE 2013, 8, e59645. [Google Scholar] [CrossRef]
- Jedema, H.P.; Song, X.; Aizenstein, H.J.; Bonner, A.R.; Stein, E.A.; Yang, Y.; Bradberry, C.W. Long-Term Cocaine Self-administration Produces Structural Brain Changes That Correlate With Altered Cognition. Biol. Psychiatry 2021, 89, 376–385. [Google Scholar] [CrossRef]
- Meade, C.S.; Bell, R.P.; Towe, S.L.; Hall, S.A. Cocaine-related alterations in fronto-parietal gray matter volume correlate with trait and behavioral impulsivity. Drug Alcohol Depend. 2020, 206, 107757. [Google Scholar] [CrossRef]
- Ahmet, O.C.; Yuefeng, H.; Greg, K.; Pias, M.; Pazia, M.; Sarah, K.; Pierre-Olivier, G.; Natalie, M.; Lily, G.; Devarshi, V.; et al. Common and distinct cortico-striatal volumetric changes in cocaine and heroin use disorder. medRxiv 2022. [Google Scholar] [CrossRef]
- Baumgartner, M.R.; Bolla, K.I.; Hulka, L.M.; Jenni, D.; Preller, K.H.; Quednow, B.B.; Stohler, R.; Vonmoos, M. Cognitive dysfunctions in recreational and dependent cocaine users: Role of attention-deficit hyperactivity disorder, craving and early age at onset. Br. J. Psychiatry 2013, 203, 35–43. [Google Scholar] [CrossRef]
- Vonmoos, M.; Hulka, L.M.; Preller, K.H.; Minder, F.; Baumgartner, M.R.; Quednow, B.B. Cognitive impairment in cocaine users is drug-induced but partially reversible: Evidence from a longitudinal study. Neuropsychopharmacology 2014, 39, 2200–2210. [Google Scholar] [CrossRef]
- Mahoney, J.J. Cognitive dysfunction in individuals with cocaine use disorder: Potential moderating factors and pharmacological treatments. Exp. Clin. Psychopharmacol. 2019, 27, 203–214. [Google Scholar] [CrossRef]
- Frazer, K.M.; Richards, Q.; Keith, D.R. The long-term effects of cocaine use on cognitive functioning: A systematic critical review. Behav. Brain Res. 2018, 348, 241–262. [Google Scholar] [CrossRef]
- Illés, A.; Balicza, P.; Molnár, V.; Bencsik, R.; Szilvási, I.; Molnar, M.J. Dynamic interaction of genetic risk factors and cocaine abuse in the background of Parkinsonism—A case report. BMC Neurol. 2019, 19, 260. [Google Scholar] [CrossRef]
- Fu, X.; Chen, T.; Cai, J.; Liu, B.; Zeng, Y.; Zhang, X. The Microbiome–Gut–Brain Axis, a Potential Therapeutic Target for Substance-Related Disorders. Front. Microbiol. 2021, 12, 738401. [Google Scholar] [CrossRef]
- Leclercq, S.; Matamoros, S.; Cani, P.D.; Neyrinck, A.M.; Jamar, F.; Starkel, P.; Windey, K.; Tremaroli, V.; Backhed, F.; Verbeke, K.; et al. Intestinal permeability, gut-bacterial dysbiosis, and behavioral markers of alcohol-dependence severity. Proc. Natl. Acad. Sci. USA 2014, 111, E4485–E4493. [Google Scholar] [CrossRef] [PubMed]
- Assis, M.A.; Carranza, P.G.; Ambrosio, E. A “Drug-Dependent” Immune System Can Compromise Protection against Infection: The Relationships between Psychostimulants and HIV. Viruses 2021, 13, 722. [Google Scholar] [CrossRef] [PubMed]
- Stamatovich, S.N.; Lopez-Gamundi, P.; Suchting, R.; Colpo, G.D.; Walss-Bass, C.; Lane, S.D.; Schmitz, J.M.; Wardle, M.C. Plasma pro- and anti-inflammatory cytokines may relate to cocaine use, cognitive functioning, and depressive symptoms in cocaine use disorder. Am. J. Drug Alcohol Abus 2021, 47, 52–64. [Google Scholar] [CrossRef]
- Albanesi, M.; Chaoul, N.; Zurlo, M.; Monitillo, F.; Pedote, P.; Procacci, V. Immunology in emergency medicine: Tetrahydrocannabinol and cocaine abuse induces neutrophils and cd19 + b-cell expansion. Authorea Prepr. 2024. [Google Scholar] [CrossRef]
- Kiraly, D.D.; Walker, D.M.; Calipari, E.S.; Labonte, B.; Issler, O.; Pena, C.J.; Ribeiro, E.A.; Russo, S.J.; Nestler, E.J. Alterations of the Host Microbiome Affect Behavioral Responses to Cocaine. Sci. Rep. 2016, 6, 35455. [Google Scholar]
- Scorza, C.; Piccini, C.; Martinez Busi, M.; Abin Carriquiry, J.A.; Zunino, P. Alterations in the Gut Microbiota of Rats Chronically Exposed to Volatilized Cocaine and Its Active Adulterants Caffeine and Phenacetin. Neurotox. Res. 2019, 35, 111–121. [Google Scholar] [CrossRef]
- Chivero, E.T.; Ahmad, R.; Thangaraj, A.; Periyasamy, P.; Kumar, B.; Kroeger, E.; Feng, D.; Guo, M.L.; Roy, S.; Dhawan, P.; et al. Cocaine Induces Inflammatory Gut Milieu by Compromising the Mucosal Barrier Integrity and Altering the Gut Microbiota Colonization. Sci. Rep. 2019, 9, 12187. [Google Scholar] [CrossRef]
- Garcia-Cabrerizo, R.; Carbia, C.; KJ, O.R.; Schellekens, H.; Cryan, J.F. Microbiota-gut-brain axis as a regulator of reward processes. J. Neurochem. 2021, 157, 1495–1524. [Google Scholar] [CrossRef] [PubMed]
- Volpe, G.E.; Ward, H.; Mwamburi, M.; Dinh, D.; Bhalchandra, S.; Wanke, C.; Kane, A.V. Associations of cocaine use and HIV infection with the intestinal microbiota, microbial translocation, and inflammation. J. Stud. Alcohol Drugs 2014, 75, 347–357. [Google Scholar] [CrossRef] [PubMed]
- Fu, X.; Cheng, D.; Luo, Z.; Wagner, A.; Fitting, S.; Cong, X.; Xu, W.; Maas, K.; Wan, Z.; Zhu, J.; et al. Oral Enrichment of Streptococcus and its Role in Systemic Inflammation Related to Monocyte Activation in Humans with Cocaine Use Disorder. J. Neuroimmune Pharmacol. 2022, 17, 305–317. [Google Scholar] [CrossRef] [PubMed]
- Gerace, E.; Baldi, S.; Salimova, M.; Di Gloria, L.; Curini, L.; Cimino, V.; Nannini, G.; Russo, E.; Pallecchi, M.; Ramazzotti, M.; et al. Oral and fecal microbiota perturbance in cocaine users: Can rTMS-induced cocaine abstinence support eubiosis restoration? iScience 2023, 26, 106627. [Google Scholar] [CrossRef] [PubMed]
- Baldi, S.; Gerace, E.; Mannaioni, G.; Amedei, A. Yin and Yang of Gut Microbiota in Cocaine Abuse. Front. Biosci.-Landmark 2024, 29, 215. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Carbone, M.G.; Maremmani, I. Chronic Cocaine Use and Parkinson’s Disease: An Interpretative Model. Int. J. Environ. Res. Public Health 2024, 21, 1105. https://doi.org/10.3390/ijerph21081105
Carbone MG, Maremmani I. Chronic Cocaine Use and Parkinson’s Disease: An Interpretative Model. International Journal of Environmental Research and Public Health. 2024; 21(8):1105. https://doi.org/10.3390/ijerph21081105
Chicago/Turabian StyleCarbone, Manuel Glauco, and Icro Maremmani. 2024. "Chronic Cocaine Use and Parkinson’s Disease: An Interpretative Model" International Journal of Environmental Research and Public Health 21, no. 8: 1105. https://doi.org/10.3390/ijerph21081105